Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Cobertura acelerada del colgajo en traumatismos graves de las extremidades inferiores (FLAP ATTACK)

15 de septiembre de 2026 actualizado por: Johns Hopkins University

Cobertura acelerada del colgajo versus sincronización estándar en el tratamiento de lesiones musculoesqueléticas graves de las extremidades inferiores

The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility).

This is the vanguard and international part of the FLAP ATTACK trial.

Descripción general del estudio

Descripción detallada

Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.

The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.

The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

356

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Lily Mundy, MD
  • Número de teléfono: 410-706-2492
  • Correo electrónico: LMundy3@jhu.edu

Ubicaciones de estudio

    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Reclutamiento
        • The Alfred Hospital
        • Contacto:
          • Lipi Shukla, MBBS, PhD
        • Investigador principal:
          • Lipi Shukla, MBBS, PhD
    • British Columbia
      • Vancouver, British Columbia, Canadá, V5Z 1N1
        • Reclutamiento
        • Vancouver General Hospital
        • Contacto:
    • New Brunswick
      • Saint John, New Brunswick, Canadá, E2L 4L2
        • Reclutamiento
        • Saint John Regional Hospital
        • Contacto:
          • Alison Wong, MD
          • Número de teléfono: 506-648-6000
          • Correo electrónico: alison.wong@dal.ca
      • Barcelona, España, 08035
        • Reclutamiento
        • Vall d'Hebron University Hospital
        • Contacto:
          • Jordi Tomás-Hernández, MD
        • Investigador principal:
          • Antonio Bulla, MD, PhD
        • Investigador principal:
          • Jordi Tomás-Hernández, MD
    • California
      • Sacramento, California, Estados Unidos, 95817
        • Reclutamiento
        • UC Davis Medical Center
        • Contacto:
          • Ara A Salibian, MD
        • Investigador principal:
          • Ara A Salibian, MD
        • Investigador principal:
          • Augustine M Saiz, MD
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Reclutamiento
        • The Johns Hopkins Hospital
        • Contacto:
          • Lily R Mundy, MD
        • Investigador principal:
          • Lily R Mundy, MD
      • Baltimore, Maryland, Estados Unidos, 21224
        • Reclutamiento
        • John Hopkins Bayview Medical Center
        • Contacto:
          • Lily R Mundy, MD
        • Investigador principal:
          • Lily R Mundy, MD
      • Baltimore, Maryland, Estados Unidos, 21201
        • Reclutamiento
        • R Adams Cowley Shock Trauma Center
        • Contacto:
          • Mark J Gage, MD
        • Investigador principal:
          • Mark J Gage, MD
      • Largo, Maryland, Estados Unidos, 20774
        • Reclutamiento
        • University of Maryland Capital Region Medical Center
        • Contacto:
          • Todd Jaeblon, MD
        • Investigador principal:
          • Todd Jaeblon, MD
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Reclutamiento
        • Oregon Health & Science University
        • Contacto:
          • Graham J DeKeyser, MD
        • Investigador principal:
          • Graham J DeKeyser, MD
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • Vanderbilt University Medical Center
        • Contacto:
          • Lauren M Tatman, MD
        • Investigador principal:
          • Lauren M Tatman, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

The inclusion criteria are:

  1. Patients 18 years of age or older.
  2. Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
  3. Will have all planned flap surgeries performed by a participating surgeon or delegate.
  4. Able to be randomized within 48 hours of injury.

The exclusion criteria are:

  1. Site is unable to implement the accelerated flap protocol due to local logistics.
  2. Primary amputation anticipated prior to attempted flap for management of the injury.
  3. Critical limb ischemia that requires re-vascularization for limb perfusion.
  4. Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
  5. Burns at the musculoskeletal injury site.
  6. Incarceration.
  7. Expected injury survival of less than 12 months.
  8. Terminal illness with expected survival of less than 12 months.
  9. Currently enrolled in a trial that does not permit co-enrollment.
  10. Declined to provide informed consent.
  11. Unable to obtain informed consent due to language barriers.
  12. Unable to obtain informed consent because a legally authorized representative was unavailable.
  13. Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
  14. Prior enrollment in the trial.
  15. Eligible patient or LAR was not approached within screening window (missed participant).
  16. Other reason to exclude the patient, as approved by the Principal Investigators.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Accelerated Flap Coverage

Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.

Timing of the flap surgery is with a goal of 72 hours from injury

Comparador activo: Standard of Care Flap Timing

The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups.

Timing of the flap surgery is the standard of care flap timing for the participating institution.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical status
Periodo de tiempo: 6 months

Clinical status is a hierarchical composite of the following outcomes:

  1. All-cause mortality
  2. Amputation related to injury
  3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure)
  4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility)
6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mortality
Periodo de tiempo: 6 months and 12 months

All-cause mortality. Mortality will be time-to-event, with the assumption that earlier is worse than later.

6 months and 12 months
Amputation
Periodo de tiempo: 6 months and 12 months

Amputation related to injury. Amputation will be time-to-event, with the assumption that earlier is worse than later.

6 months and 12 months
Unplanned re-operation
Periodo de tiempo: 6 months and 12 months

Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure). Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse.

6 months and 12 months
Number of days in hospital
Periodo de tiempo: 6 months and 12 months

Days in an acute in-patient hospital (i.e., not rehab or nursing facility)

6 months and 12 months
Patient-reported health status as assessed by the Euro-QoL (EQ-5D-5L)
Periodo de tiempo: 6 months and 12 months

Patient-reported health status as assessed by the EQ-5D-5L. The EQ-5D-5L is scored on a 0 to 100 mm scale. 0 mm represents "the worst health you can imagine to 100 mm which represents "the best health you can imagine".

6 months and 12 months
Quality of life as assessed by the Limb-Q
Periodo de tiempo: 6 months and 12 months

Health-related quality of life and patient satisfaction measured with the Limb-Q. The Limb-Q is a set of independently functioning scales. All scales are scored 0-100 (higher = better). The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used.

6 months and 12 months
Clinical Status
Periodo de tiempo: 12 months

Clinical status is a hierarchical composite of the following outcomes: 1. All-cause mortality 2. Amputation related to injury 3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure) 4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility)

12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Lily Mundy, MD, Johns Hopkins School of Medicine

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de noviembre de 2024

Finalización primaria (Estimado)

1 de agosto de 2029

Finalización del estudio (Estimado)

1 de febrero de 2030

Fechas de registro del estudio

Enviado por primera vez

28 de febrero de 2024

Primero enviado que cumplió con los criterios de control de calidad

28 de febrero de 2024

Publicado por primera vez (Actual)

5 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • IRB00434587

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir